Pharmafile Logo

dapagliflozin

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

AstraZeneca’s phase 3 liver cancer study shows continued survival benefit

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

AstraZeneca and Quell announce autoimmune disease partnership worth over $2bn

The collaboration will initially focus on developing cell therapies for type 1 diabetes and IBD

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

AstraZeneca to stop post-marketing study of Andexxa following early success

The company will now seek full approvals for the bleeding reversal agent in the US and EU

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Crick Institute announces new molecular glue discovery to treat different diseases

The £11.2m research investment includes funds from AstraZeneca and the EPSRC

- PMLiVE

AstraZeneca’s heart failure treatment recommended by NICE for expanded use

More than 550,000 patients have a confirmed heart failure diagnosis in England alone

- PMLiVE

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in US

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

AstraZeneca presents positive phase 3 results for Imfinzi regimen in lung cancer

Around 2.2 million people are diagnosed with lung cancer globally each year

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links